Advanced Functional Materials · 2021 · 73 citations · 51 references
PharmacyOncologyPharmaceuticsDrug DeliveryNanoparticle Drug DeliveryTargeted Drug DeliveryCancer Drug DeliveryCancer NanomedicineNanomedicineNanoparticle FormulationsNucleic Acid DeliverySmall Interfering Rna DeliveryDrug Delivery NanocarriersEndosomal Escape DesignNanocarriersNanoparticle Cellular UptakeNanoparticle DeliveryNanoparticlesPolymeric NanocarriersTherapeutic Small Interfering Rna
Clinical translation of polymer-based nanocarriers for systemic delivery of RNA has been limited due to poor colloidal stability in the blood stream and intracellular delivery of the RNA to the cytosol. To address these limitations, this study reports a new strategy incorporating photocrosslinking of bioreducible nanoparticles for improved stability extracellularly and rapid release of RNA intracellularly. In this design, the polymeric nanocarriers contain ester bonds for hydrolytic degradation and disulfide bonds for environmentally triggered small interfering RNA (siRNA) release in the cytosol. These photocrosslinked bioreducible nanoparticles (XbNPs) have a shielded surface charge, reduced adsorption of serum proteins, and enable superior siRNA-mediated knockdown in both glioma and melanoma cells in high-serum conditions compared to non-crosslinked formulations. Mechanistically, XbNPs promote cellular uptake and the presence of secondary and tertiary amines enables efficient endosomal escape. Following systemic administration, XbNPs facilitate targeting of cancer cells and tissue-mediated siRNA delivery beyond the liver, unlike conventional nanoparticle-based delivery. These attributes of XbNPs facilitate robust siRNA-mediated knockdown in vivo in melanoma tumors colonized in the lungs following systemic administration. Thus, biodegradable polymeric nanoparticles, via photocrosslinking, demonstrate extended colloidal stability and efficient delivery of RNA therapeutics under physiological conditions, and thereby potentially advance systemic delivery technologies for nucleic acid-based therapeutics.
51
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao, Qiulian Wu, Roger E. McLendon et al. · Nature · 2006 · 6.4K citations
Medicine, Cancer Biology, Oncology +16
Tommy Cedervall, Iseult Lynch, Stina Lindman et al. · Proceedings of the National Academy of Sciences · 2007 · 3.2K citations · Full text